Form 8-K - Current report:
SEC Accession No. 0001493152-23-007535
Filing Date
2023-03-14
Accepted
2023-03-14 08:08:06
Documents
14
Period of Report
2023-03-14
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 36510
2 ex99-1.htm EX-99.1 16758
3 ex99-1_001.jpg GRAPHIC 5423
  Complete submission text file 0001493152-23-007535.txt   239879

Data Files

Seq Description Document Type Size
4 INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT envb-20230314.xsd EX-101.SCH 3224
5 INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT envb-20230314_lab.xml EX-101.LAB 34240
6 INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT envb-20230314_pre.xml EX-101.PRE 22357
8 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3610
Mailing Address 4851 TAMIAMI TRAIL N, SUITE 200 NAPLES FL 34103
Business Address 4851 TAMIAMI TRAIL N, SUITE 200 NAPLES FL 34103 239-302-1707
Enveric Biosciences, Inc. (Filer) CIK: 0000890821 (see all company filings)

EIN.: 954484725 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38286 | Film No.: 23729233
SIC: 2834 Pharmaceutical Preparations